Skip To Main Content

ONU receives grant to study new aspirin dosage form

Dec 19, 2007
The Ohio Northern University Raabe College of Pharmacy, working with the nursing program, has received a $26,000 grant from Improvita Health Products Inc. of Cleveland to perform a clinical study of their Fasprin® product.

ONU will conduct on-campus clinical research to determine how fast aspirin from Fasprin® enters into the bloodstream. Unlike traditional aspirins, Fasprin® dissolves in the mouth (not in the stomach), which may allow it to work quicker than other aspirin products on the market.

Dr. David Kisor, ONU associate professor of pharmacokinetics, will serve as the principal investigator for the study. ONU professors of pharmacy Drs. Yousif Rojeab, B. Shane Martin and Darrell Hulisz will assist.

Dr. Bruce Bouts, BSPH '82, will serve as the study physician. Marjorie Walker, director of ONU's nursing program; Mary McWilliams, assistant professor of nursing; Robin White, assistant professor of nursing; and Susan Montenery, assistant professor of nursing, also will participate.

Three ONU fifth-year pharmacy students will assist in the project: Jason Martinez, of Medina, Ohio; Kate Turkaly, of Pittsburgh, Pa., and Matthew Tupps, of Bucyrus, Ohio. In addition, a number of ONU students have volunteered to be research subjects.

"This clinical study being performed at ONU is another example of the dedicated research effort at our University," Kisor said. "This study will provide great experience for our students, and we are excited about the chance to work on such an endeavor."

Kisor said that the study will confirm the time course of aspirin being delivered to the blood from the Fasprin® product. He points out that low-dose aspirin has a number of indications for use, including reducing the risk of death in patients with suspected heart attacks. He added that the drug formulation might be beneficial to certain individuals, such as those who have trouble swallowing tablets or those who may experience direct stomach irritation from aspirin products.

The research group expects to complete the study in January. The results will be presented to the sponsor in February, and the information eventually will be published.